| Name | Title | Contact Details |
|---|
Mymcpl is a Missouri-based nonprofit organization that provides notary, remote printing, and passport services for individuals.
Mazars is an internationally integrated partnership, specialising in audit, accountancy, advisory, tax and legal services*. Operating in over 100 countries and territories around the world, we draw on the expertise of more than 50,000 professionals – 33,000+ in Mazars integrated partnership and 17,000+ via the Mazars North America Alliance – to assist clients of all sizes at every stage in their development. *Where permitted under applicable country laws
Harvey Performance Company, established in 1985 and based in Rowley, Massachusetts, is a prominent designer and manufacturer of specialty carbide cutting tools for precision machining. The company operates under five brands: Harvey Tool, Helical Solutions, Micro 100, Titan USA, and CoreHog, with additional facilities in Gorham, Maine; Meridian, Idaho; and West Springfield, Massachusetts. With a workforce of around 350 employees, it is led by President and CEO Peter Jenkins. The company specializes in high-performance cutting tools, including micro-tools, end mills, and custom tooling solutions, tailored for industries such as aerospace, medical devices, electronics, telecommunications, and general machining. Harvey Performance is known for its fast service, comprehensive product support, and technical expertise, catering to manufacturers that require extreme precision and tight tolerances. The company also actively participates in community initiatives and workforce development, supporting local technical schools and charitable events.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
With so much conflicting and confusing information surrounding Medicare, its easy to feel unsure about how to choose the best plan(s). At MedicareSchool.com, we empower you with the knowledge and guidance you need to get the best Medicare plans and live retirement worry-free.